This Article Abstract Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Nicholls, S. J. Articles by Nissen, S. E. Search for Related Content PubMed Articles by Nicholls, S. J. Articles by Nissen, S. E. Related Collections Related Articles

CLINICAL RESEARCH: CORONARY ARTERY DISEASE

Effect of Diabetes on Progression of Coronary Atherosclerosis and Arterial Remodeling

A Pooled Analysis of 5 Intravascular Ultrasound Trials

Stephen J. Nicholls, MBBS, PhD^_*,,_*, E. Murat Tuzcu, MD^_*, Srinivasa Kalidindi, MD, MPH^_*, Kathy Wolski, MPH^_*, Keon-W. Moon, MD^_*, Ilke Sipahi, MD^_*, Paul Schoenhagen, MD^_* and Steven E. Nissen, MD^_*

^_* Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
Department of Cell Biology, Cleveland Clinic, Cleveland, Ohio.

Manuscript received December 13, 2007; revised manuscript received March 7, 2008, accepted March 11, 2008.

^_* Reprint requests and correspondence: Dr. Stephen J. Nicholls, Department of Cardiovascular Medicine, Mail Code JJ-65, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195. (Email: nichols1{at}ccf.org).

	Abstract

Top Abstract Methods Results Discussion Conclusions References

 
Objectives: Our goal was to characterize coronary atherosclerosis progression and arterial remodeling in diabetic patients.

Background: The mechanisms that underlie adverse cardiovascular outcomes in diabetic patients have not been well characterized.

Methods: A systematic analysis was performed in 2,237 subjects in randomized controlled studies of atherosclerosis progression. The pattern of arterial remodeling, extent of coronary atherosclerosis, and disease progression was compared in subjects with and without diabetes.

Results: In association with more risk factors, diabetic patients demonstrated a greater percent atheroma volume (PAV) (40.2 ± 0.9% vs. 37.5 ± 0.8%, p < 0.0001) and total atheroma volume (TAV) (199.4 ± 7.9 mm³ vs. 189.4 ± 7.1 mm³, p = 0.03) on multivariate analysis. A stronger correlation was observed between PAV and glycated hemoglobin (r = 0.22, p = 0.0003) than fasting glucose (r = 0.09, p < 0.0001), although the difference just failed to meet statistical significance after controlling for study. Diabetic patients exhibited a smaller lumen (291.1 ± 104.8 mm³ vs. 306.5 ± 108.2 mm³, p = 0.005) but no difference in external elastic membrane (494.9 ± 166.9 mm³ vs. 498.8 ± 167.2 mm³, p = 0.61) volumes. More rapid progression of PAV (0.6 ± 0.4% vs. 0.05 ± 0.3%, p = 0.0001) and TAV (–0.6 ± 2.5 mm³ vs. –2.7 ± 2.4 mm³, p = 0.03) was observed in diabetic patients on multivariate analysis. Smaller external elastic membrane (482.5 ± 160.7 mm³ vs. 519.9 ± 166.9 mm³, p = 0.03) and lumen (276.0 ± 100.3 mm³ vs. 310.1 ± 105.6 mm³, p = 0.001) volumes were observed in diabetic patients treated with insulin despite the presence of a similar TAV (206.5 ± 88.6 mm³ vs. 209.9 ± 90.2 mm³, p = 0.84). Intensive low-density lipoprotein cholesterol lowering in patients improved the rate of plaque progression, but only to the level observed in nondiabetic patients with suboptimal lipid control.

Conclusions: Diabetes is accompanied by more extensive atherosclerosis and inadequate compensatory remodeling. Accelerated plaque progression, despite use of medical therapies, supports the need to develop new antiatherosclerotic strategies in diabetic patients.

Key Words: diabetes • atherosclerosis • intravascular ultrasound • coronary artery disease • risk factors

Abbreviations and Acronyms   CRP = C-reactive protein   EEM = external elastic membrane   HDL = high-density lipoprotein   IVUS = intravascular ultrasound   LDL = low-density lipoprotein   PAV = percent atheroma volume   TAV = total atheroma volume

Elucidating the factors that promote cardiovascular disease in diabetes is critical for the development of new therapeutic approaches. The prevalence of hyperglycemia, hypertension, and dyslipidemia, in association with systemic inflammation and oxidative stress, accelerates the formation and propagation of atherosclerotic plaque (13). This underlies observations from small clinical (15–17) and necropsy (18,19) studies that diabetes is characterized by diffuse atherosclerosis, with a predilection for involvement of distal segments in relatively small vessels. However, no systematic assessment of the pattern of coronary atherosclerosis and associated arterial wall remodeling has been performed in a large cohort of diabetic patients by imaging of the entire thickness of the coronary artery wall.

Intravascular ultrasound (IVUS) permits evaluation of the influence of clinical characteristics on changes in coronary atheroma volume (20,21). More recently, IVUS has been employed to assess the impact of medical therapies on the natural history of plaque progression (22–26). The current study investigated the extent and progression of atherosclerosis and associated arterial wall remodeling in a large number of diabetic patients with coronary artery disease who underwent serial evaluation by IVUS.

	Methods

Top Abstract Methods Results Discussion Conclusions References

 
Subject selection.   Subjects participated in the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) (22), CAMELOT (Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis) (23), ACTIVATE (Acyl:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation) (24), ASTEROID (A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden) (25), and ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by Cholesteryl Ester Transfer Protein Inhibition and High-Density Lipoprotein Elevation) (26) studies. These were clinical trials that employed serial IVUS examination to assess the impact of intensive lipid lowering, antihypertensive therapy, experimental acyl:cholesterol acyltransferase inhibition, or cholesterol ester transfer protein inhibition on the progression of coronary atherosclerosis. All patients were required to have coronary artery disease, defined as having at least 1 lumen narrowing >20% in a major epicardial coronary artery on a diagnostic coronary angiogram performed for a clinical indication.

Acquisition and analysis of IVUS images.   The acquisition and analysis of ultrasonic images have been described in detail previously (22–26). In brief, after anticoagulation and administration of intracoronary nitroglycerin, an imaging catheter containing a high-frequency ultrasound transducer (30 to 40 MHz) was inserted as far as distally possible within a coronary artery. The target vessel for imaging was required to have a segment of at least 30 mm in length that contained no lumen narrowing >50%, had not undergone previous revascularization, and was not considered to be the culprit vessel for a prior myocardial infarction. Continuous ultrasonic imaging was acquired during withdrawal of the catheter through the segment of artery at a constant rate of 0.5 mm/s. Images were stored on videotape and subsequently digitized for analysis in a single core laboratory by individuals who were blinded to the clinical characteristics and treatment status of the patients.

Matching arterial segments were defined from the images acquired at the baseline and follow-up studies on the basis of the anatomic location of proximal and distal side branches (fiduciary points). Images spaced precisely 1 mm apart in the segment of interest were selected for analysis. The leading edge of the lumen and the external elastic membrane (EEM) were defined by manual planimetry. The plaque area was defined as the difference in area occupied by the lumen and EEM borders. The total atheroma volume (TAV) was calculated by summation of the plaque area calculated for each measured image and subsequently normalized to account for differences in segment length between subjects:

The percent atheroma volume (PAV) was also calculated by determination of the proportion of vessel wall volume occupied by atherosclerotic plaque:

Volumes occupied by the lumen and EEM were similarly calculated by summation of their respective areas in each measured image and subsequently normalized to account for differences in segment length between subjects.

Statistical analysis.   All analyses were performed using SAS version 8.2 (SAS Institute, Cary, North Carolina). Results are expressed as mean ± SD for continuous variables and percentage for categorical variables. Continuous variables that are not normally distributed (triglycerides, C-reactive protein [CRP]) are expressed as median (interquartile range). Comparisons between diabetic and nondiabetic groups were performed using a random effects model to account for any potential differences between each individual study that was pooled for the current analysis (Cochrane's Q statistic 8.9, p = 0.06 and I² = 55%, indicating moderate heterogeneity). Changes in atheroma burden were expressed as the least square mean ± SEM after controlling for baseline values. The relationships between biochemical parameters and measures of atheroma burden and between changes in vessel dimensions were determined by calculation of the Pearson correlation coefficient. A p value <0.05 was considered statistically significant.

	Results

Top Abstract Methods Results Discussion Conclusions References

 
Clinical characteristics.   Clinical characteristics are summarized in Table 1. Diabetic subjects were more likely to be women (32.7% vs. 26.3%, p = 0.008) and African American (7.9% vs. 4.0%, p = 0.001), had a greater body mass index (32.4 ± 6.3 kg/m² vs. 29.7 ± 5.2 kg/m², p < 0.001), and had a greater prevalence of hypertension (87.5% vs. 72.2%, p < 0.001) and hyperlipidemia (74.3% vs. 67.1%, p = 0.004). Subjects with diabetes were more likely to meet the criteria for the metabolic syndrome (77.1% vs. 41.2%, p < 0.001). Diabetic subjects were more likely to have undergone a previous percutaneous coronary intervention (52.7% vs. 43.2%, p = 0.001), were more likely to be treated with an angiotensin-converting enzyme inhibitor (65.1% vs. 47.6%, p < 0.001), and were less likely to receive aspirin (91.8% vs. 94.8%, p = 0.02). Among diabetic subjects, 37.0% were treated with insulin and 69.5% received an oral hypoglycemic agent.

Serial changes in atheroma burden and vessel dimensions.   Changes in atheroma burden and vascular dimensions during serial evaluation are summarized in Table 4. Greater progression of PAV was observed in diabetic subjects (0.8 ± 3.4% vs. 0.3 ± 3.3%, p = 0.003). Diabetic subjects were also more likely to undergo substantial atheroma progression (>5% relative increase in PAV, 30.3% vs. 23.2%, p = 0.002) and less likely to undergo substantial atheroma regression (>5% relative decrease in PAV, 15.9% vs. 20.3%, p = 0.04). Multivariate analysis revealed that the presence of diabetes was an independent predictor of progression of both PAV (p = 0.0001) and TAV (p = 0.03). A closer relationship was observed between baseline levels of glycated hemoglobin (n = 280), compared with fasting glucose (n = 2,216), with changes in TAV (r = 0.14, p = 0.02 vs. r = 0.02, p = 0.29), with the difference between these markers of glycemic control reaching statistical significance (p = 0.02). When controlling for study, the difference in correlation between glycated hemoglobin and fasting glucose for the change in TAV (r = 0.04 vs. r = 0.02) was not significant (p = 0.72). No significant differences were observed between groups with regard to changes in vascular dimensions. Changes in atheroma volume were accompanied by changes in EEM (r = 0.58, p < 0.0001 vs. r = 0.62, p < 0.0001) but not lumen (r = –0.02, p = 0.72 vs. r = 0.06, p = 0.008) in both diabetic and nondiabetic subjects, respectively.

Intensive lowering of LDL cholesterol and CRP and atheroma progression.   The impact of intensive lowering of levels of LDL cholesterol below 80 mg/dl on progression of coronary atherosclerosis is summarized in Figure 1. Intensive lowering of LDL cholesterol had a beneficial impact on progression of PAV in both diabetic (0.4 ± 3.2% vs. 1.3 ± 3.6%, p = 0.008) and nondiabetic (–0.2 ± 3.0% vs. 0.6 ± 3.5%, p < 0.001) subjects and on progression of TAV in diabetic subjects (–5.0 ± 21.7 mm³ vs. 2.2 ± 24.8 mm³, p = 0.001) and nondiabetic subjects (–6.9 ± 19.5 mm³ vs. –1.5 ± 23.3 mm³, p < 0.001). Intensive lowering of LDL cholesterol also resulted in a greater proportion of subjects undergoing substantial regression (at least 5% relative reduction in PAV) in diabetic subjects (18.5% vs. 13.0%, p = 0.12) and nondiabetic subjects (23.4% vs. 17.5%, p = 0.002). The proportion of subjects undergoing substantial progression (at least 5% relative increase in PAV) was reduced with intensive lowering of LDL cholesterol in both diabetic subjects (26.9% vs. 35.2%, p = 0.07) and nondiabetic subjects (18.4% vs. 27.4%, p < 0.001). Of interest, intensive lowering of LDL cholesterol only improved progression rates of diabetic subjects to that observed in the nondiabetic subject without intensive control of LDL cholesterol. The impact of intensive lowering of CRP was investigated in subjects in whom CRP measurements were available (n = 1,727). While a similar trend was observed with regard to achieving a CRP level <2 mg/l, none of the comparisons achieved statistical significance (Fig. 2).

View larger version (16K): [in this window] [in a new window] [Download PPT slide]   Figure 1 LDL Lowering and Plaque Progression Changes in percent atheroma volume (PAV) (top left) and total atheroma volume (TAV) (top right) and proportion of subjects undergoing substantial regression (at least 5% relative decrease in PAV, bottom left) and progression (at least 5% relative increase in percent atheroma volume, bottom right) in patients with and without diabetes mellitus (DM) stratified according to a level of low-density lipoprotein cholesterol (LDL-C) < or >80 mg/dl with treatment. LDL = low-density lipoprotein.

View larger version (16K): [in this window] [in a new window] [Download PPT slide]   Figure 2 CRP Lowering and Plaque Progression Changes in PAV (top left) and TAV (top right) and proportion of subjects undergoing substantial regression (at least 5% relative decrease in percent atheroma volume, bottom left) and progression (at least 5% relative increase in percent atheroma volume, bottom right) in patients with and without DM stratified according to a level of C-reactive protein (CRP) < or >2 mg/l with treatment. Abbreviations as in Figure 1.

	Discussion

Top Abstract Methods Results Discussion Conclusions References

The presence of more extensive disease confirms through direct observations of the vessel wall the finding that diabetic patients have an accelerated form of atherosclerotic disease. A number of pathophysiologic abnormalities likely explain the more rapid progression of disease. The presence of diabetes is accompanied by a greater prevalence of established atherosclerotic risk factors including hypertension; low levels of HDL cholesterol; hypertriglyceridemia; the presence of small, dense LDL particles; and obesity. However, conventional risk factors alone represent only a portion of the excess disease burden. Hyperglycemia and the potential generation of advanced glycation end products also seem to play an important role (27). The chronic influence of hyperglycemia is supported by the observation of a correlation between measures of atheroma burden and glycated hemoglobin, a marker of long-term glycemic control. The presence of elevated systemic markers of inflammation and oxidative stress provide additional mechanisms that may contribute to the accelerated form of atherosclerosis.

The current observations also suggest that abnormalities of arterial remodeling may influence the clinical expression of disease in diabetes. Angiographic studies in diabetics typically reveal diffuse disease with a predilection for distal segments of relatively small vessels (28). The current findings suggest that the pattern of disease in diabetes is not more diffuse in the patient with angiographic abnormalities. Indeed, the presence of more extensive atherosclerosis involving a similar proportion of images is consistent with a pattern of disease that may be more focal than previously considered. The finding that lumen volumes are smaller in the diabetic subjects is consistent with the observation of smaller vessels on angiography. A similar EEM volume and smaller lumen, despite the presence of more extensive atherosclerosis, suggests that diabetes is accompanied by impaired compensatory remodeling of the arterial wall. The mechanisms that promote impaired arterial remodeling in diabetes remain to be defined. However, it is possible that increasing deposition of fibrous (29,30) and calcific (31) tissue in the arterial wall, in addition to impaired endothelial-dependent relaxation (32), may limit vessel wall expansion with plaque accumulation. Given its role in the promotion of obstructive disease, inadequate arterial remodeling represents an additional target for therapeutic modification in diabetic patients with coronary artery disease.

Impairment of compensatory remodeling appears to be prominent in diabetic patients treated with insulin and supports previous observations in studies of native atherosclerosis (33,34) and heart transplant recipients (35). These patients demonstrated smaller vascular dimensions and a greater PAV, despite the presence of a similar TAV. This suggests that inadequate compensatory remodeling is particularly evident in the insulin-treated patient. Proliferation of smooth muscle and fibrous tissue in response to insulin (36) might increase vascular stiffness and further impair the ability of the artery wall to expand in response to accumulation of plaque.

This study provides insight into the impact of established medical therapies on atheroma progression in the setting of diabetes. In previous studies of patients with established coronary artery disease, lipid-modifying therapies slowed progression of obstructive disease by angiography (37). This is consistent with the observation that the greatest clinical benefit of medical management of diabetic patients is derived from optimal control of blood pressure (38) and lipids (39–41). However, despite the high rate of use of blood pressure and lipid-modifying therapies, accelerated disease progression was observed in diabetic patients. Furthermore, while intensive lowering of LDL cholesterol had a favorable impact on plaque progression, the diabetic subjects continued to demonstrate greater increases in atheroma volume. This residual progression suggests that an incremental benefit might be derived from use of emerging medical therapies, which modify additional targets including hyperglycemia and inflammatory mediators of disease in the arterial wall. The more recent observation that improving control of glycemic, lipid, and inflammatory markers with the peroxisome proliferator-activated receptor-gamma agonist pioglitazone slows progression of carotid intimal-medial thickness (42) suggests that this strategy may also have a beneficial impact on established coronary atherosclerosis.

Study limitations.   A number of caveats should be noted with regard to the current analysis. The results of this analysis were obtained by pooling data from a number of clinical trials. The diagnosis of diabetes was recorded on the basis of the clinical report form of each study. As duration of diabetes was not recorded, it is unknown whether the extent of atherosclerosis and inadequate remodeling was greater in those subjects with a longer history of impaired glycemic control. As all patients had a diagnosis of coronary artery disease at the time of a clinically indicated angiogram, it is unknown if the current findings can be translated to the setting of primary prevention. However, the observation that asymptomatic diabetic patients have a prospective cardiovascular risk comparable to that of nondiabetic survivors of myocardial infarction (14) suggests that the underlying disease is aggressive even in the patient who has yet to come to clinical attention. As the direct relationship between the extent of atherosclerosis on IVUS and clinical outcome continues to be defined, it remains to be determined to what extent the differences in plaque burden contribute to the adverse cardiovascular outcome observed in diabetic patients with established coronary artery disease.

	Conclusions

Top Abstract Methods Results Discussion Conclusions References

 
The current analysis of a large number of diabetic subjects reveals the presence of more extensive atherosclerosis in association with impaired compensatory remodeling of the arterial wall. While a benefit on disease progression is observed with the use of medical therapies, an accelerated increase in atheroma volume is observed in comparison with that seen in patients without diabetes. This finding suggests that there is an ongoing need to develop new therapies that complement modification of established risk factors to achieve a greater benefit in halting disease progression in diabetic patients resulting in optimal reduction of cardiovascular risk.

	Acknowledgments

 
The authors thank the Intravascular Ultrasound Core Laboratory of the Cleveland Clinic for its technical expertise.

	Footnotes

 
The ACTIVATE study was sponsored by Sankyo Pharmaceuticals. The ASTEROID study was sponsored by AstraZeneca Pharmaceuticals. The CAMELOT, ILLUSTRATE, and REVERSAL studies were sponsored by Pfizer Pharmaceuticals.

Dr. Nicholls has received speaking honoraria from Pfizer, Takeda, Merck, Schering-Plough, and AstraZeneca and consulting fees from Pfizer, Roche, and AstraZeneca. Dr. Tuzcu has received speaking honoraria and research support from Pfizer and AstraZeneca. Dr. Sipahi has received an educational grant from Pfizer. Dr. Nissen has received research support from AstraZeneca, Eli Lilly, Pfizer, Takeda, Sankyo, and Sanofi-Aventis; he has consulted for a number of pharmaceutical companies without financial compensation. All honoraria, consulting fees, or other payments from any for-profit entity are paid directly to charity, so that neither income nor any tax deduction is received.

	References

Top Abstract Methods Results Discussion Conclusions References

 
1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease study Lancet 1997;349:1498-1504.[CrossRef][Web of Science][Medline]

2. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies BMJ 2006;332:73-78.[Abstract/Free Full Text]

3. Ho JE, Paultre F, Mosca L. Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women?. Data from the Women's Pooling Project. Stroke 2003;34:2812-2816.[Abstract/Free Full Text]

4. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study Diabetes Care 1979;2:120-126.[Abstract]

5. McCarron P, Greenwood R, Elwood P, et al. The incidence and aetiology of stroke in the Caerphilly and Speedwell Collaborative Studies II: risk factors for ischaemic stroke Public Health 2001;115:12-20.[Web of Science][Medline]

6. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention trial Diabetes Care 1993;16:434-444.[Abstract]

7. Chun BY, Dobson AJ, Heller RF. The impact of diabetes on survival among patients with first myocardial infarction Diabetes Care 1997;20:704-708.[Abstract]

8. Donnan PT, Boyle DI, Broomhall J, et al. Prognosis following first acute myocardial infarction in type 2 diabetes: a comparative population study Diabet Med 2002;19:448-455.[CrossRef][Web of Science][Medline]

9. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA myocardial infarction register study group. Diabetes Care 1998;21:69-75.[Abstract]

10. Wannamethee G, Whincup PH, Shaper AG, Walker M, MacFarlane PW. Factors determining case fatality in myocardial infarction "who dies in a heart attack"? Br Heart J 1995;74:324-331.[Abstract/Free Full Text]

11. Ashfaq S, Ghazzal Z, Douglas JS, Morris DC, Veledar E, Weintraub WS. Impact of diabetes on five-year outcomes after vein graft interventions performed prior to the drug-eluting stent era J Invasive Cardiol 2006;18:100-105.[Medline]

12. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization JAMA 2005;293:1501-1508.[Abstract/Free Full Text]

13. Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators Am J Med 2007;120:S12-S17.[Web of Science][Medline]

14. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 1998;339:229-234.[Abstract/Free Full Text]

15. Larsen JR, Tsunoda T, Tuzcu EM, et al. Intracoronary ultrasound examinations reveal significantly more advanced coronary atherosclerosis in people with type 1 diabetes than in age- and sex-matched non-diabetic controls Diab Vasc Dis Res 2007;4:62-65.[Abstract/Free Full Text]

16. Nicholls SJ, Tuzcu EM, Crowe T, et al. Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound J Am Coll Cardiol 2006;47:1967-1975.[Abstract/Free Full Text]

17. Kornowski R, Mintz GS, Abizaid A, Leon MB. Intravascular ultrasound observations of atherosclerotic lesion formation and restenosis in patients with diabetes mellitus Int J Cardiovasc Intervent 1999;2:13-20.[Medline]

18. Burchfiel CM, Reed DM, Marcus EB, Strong JP, Hayashi T. Association of diabetes mellitus with coronary atherosclerosis and myocardial lesions. An autopsy study from the Honolulu Heart Program. Am J Epidemiol 1993;137:1328-1340.[Abstract/Free Full Text]

19. Lester WM, Roberts WC. Diabetes mellitus for 25 years or more. Analysis of cardiovascular findings in seven patients studied at necropsy. Am J Med 1986;81:275-279.[CrossRef][Web of Science][Medline]

20. von Birgelen C, Hartmann M, Mintz GS, et al. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries Circulation 2004;110:1579-1585.[Abstract/Free Full Text]

21. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Nissen SE. Intravascular ultrasound in cardiovascular medicine Circulation 2006;114:e55-e59.[Free Full Text]

22. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 2004;291:1071-1080.[Abstract/Free Full Text]

23. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial JAMA 2004;292:2217-2225.[Abstract/Free Full Text]

24. Nissen SE, Tuzcu EM, Brewer HB, et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis N Engl J Med 2006;354:1253-1263.[Abstract/Free Full Text]

25. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial JAMA 2006;295:1556-1565.[Abstract/Free Full Text]

26. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 2007;356:1304-1316.[Abstract/Free Full Text]

27. Stancoven A, McGuire DK. Preventing macrovascular complications in type 2 diabetes mellitus: glucose control and beyond Am J Cardiol 2007;99:5H-11H.[Web of Science][Medline]

28. Stone PH, Muller JE, Hartwell T, et al. The MILIS study group The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis J Am Coll Cardiol 1989;14:49-57.[Abstract]

29. Portik-Dobos V, Anstadt MP, Hutchinson J, Bannan M, Ergul A. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes Diabetes 2002;51:3063-3068.[Abstract/Free Full Text]

30. Rumble JR, Cooper ME, Soulis T, et al. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J Clin Invest 1997;99:1016-1027.[Web of Science][Medline]

31. Anand DV, Lim E, Darko D, et al. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers J Am Coll Cardiol 2007;50:2218-2225.[Abstract/Free Full Text]

32. Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases Diabetes Metab Res Rev 2006;22:423-436.[CrossRef][Web of Science][Medline]

33. Kornowski R, Mintz GS, Lansky AJ, et al. Paradoxic decreases in atherosclerotic plaque mass in insulin-treated diabetic patients Am J Cardiol 1998;81:1298-1304.[CrossRef][Web of Science][Medline]

34. Schukro C, Syeda B, Yahya N, et al. Volumetric intravascular ultrasound imaging to illustrate the extent of coronary plaque burden in type 2 diabetic patients J Diabetes Complications 2007;21:381-386.[CrossRef][Web of Science][Medline]

35. Sakurai R, Yamasaki M, Nakamura M, et al. Determinants of lumen loss between years 1 and 2 after cardiac transplantation Transplantation 2007;84:1097-1102.[Web of Science][Medline]

36. Nigro J, Osman N, Dart AM, Little PJ. Insulin resistance and atherosclerosis Endocr Rev 2006;27:242-259.[Abstract/Free Full Text]

37. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention study, a randomised study. Lancet 2001;357:905-910.[CrossRef][Web of Science][Medline]

38. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials Arch Intern Med 2005;165:1410-1419.[Abstract/Free Full Text]

39. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 2002;360:7-22.[CrossRef][Web of Science][Medline]

40. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 2004;364:685-696.[CrossRef][Web of Science][Medline]

41. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 2003;361:2005-2016.[CrossRef][Web of Science][Medline]

42. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial JAMA 2006;296:2572-2581.[Abstract/Free Full Text]

Related Articles

Diabetic Coronary Artery Disease: How Little We Know and How Little Intravascular Ultrasound Has Taught Us

Gary S. Mintz
J. Am. Coll. Cardiol. 2008 52: 263-265. [Full Text] [PDF]

This article has been cited by other articles:

				T. H. Schindler, J. Cadenas, A. D. Facta, Y. Li, M. Olschewski, J. Sayre, J. Goldin, and H. R. Schelbert Improvement in coronary endothelial function is independently associated with a slowed progression of coronary artery calcification in type 2 diabetes mellitus Eur. Heart J., November 12, 2009; (2009) ehp482v1. [Abstract] [Full Text] [PDF]

				J. Sanz, P. R. Moreno, and V. Fuster The year in atherothrombosis. J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1326 - 1337. [Full Text] [PDF]

				P. Agostoni and F. V. d. Branden Drug eluting stents in patients with diabetes BMJ, August 29, 2008; 337(aug29_3): a1359 - a1359. [Full Text]

				G. S. Mintz Diabetic Coronary Artery Disease: How Little We Know and How Little Intravascular Ultrasound Has Taught Us J. Am. Coll. Cardiol., July 22, 2008; 52(4): 263 - 265. [Full Text] [PDF]

This Article Abstract Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Nicholls, S. J. Articles by Nissen, S. E. Search for Related Content PubMed Articles by Nicholls, S. J. Articles by Nissen, S. E. Related Collections Related Articles